Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 10/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
| ▸ | GYS1 | P13807 | 3/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13586329 | 1.00 | FFAR4 (0.33) | FFAR4ACACAS1PR3S1PR5GYS1 | |
| SCHEMBL12821221 | 0.91 | ACACA (0.33) | FFAR4ACACAS1PR3S1PR5GYS1 | |
| SCHEMBL13654164 | 0.91 | ACACA (0.38) | FFAR4ACACAGYS1FFAR1 | |
| SCHEMBL12994821 | 0.91 | FFAR4 (0.33) | FFAR4S1PR3S1PR5GYS1FFAR1 | |
| SCHEMBL12718885 | 0.88 | MEN1 (0.33) | FFAR4 | |
| SCHEMBL12821216 | 0.88 | MEN1 (0.33) | FFAR4 | |
| SCHEMBL12823287 | 0.86 | FFAR4 (0.37) | FFAR4ACACAGYS1FFAR1ESR1 | |
| SCHEMBL12821213 | 0.86 | FFAR4 (0.35) | FFAR4GYS1FFAR1 | |
| SCHEMBL12906999 | 0.86 | FFAR4 (0.36) | FFAR4GYS1FFAR1 | |
| SCHEMBL13586184 | 0.86 | FFAR4 (0.35) | FFAR4GYS1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | FFAR4 546/4885ACACA 2882/4885S1PR3 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.